Previous Article | Next Article ![]()
Journal of Virology, September 1998, p. 7501-7509, Vol. 72, No. 9
The Aaron Diamond AIDS Research Center,
Received 26 January 1998/Accepted 28 May 1998
Despite evidence that live, attenuated simian immunodeficiency
virus (SIV) vaccines can elicit potent protection against
pathogenic SIV infection, detailed information on the replication
kinetics of attenuated SIV in vivo is lacking. In this study, we
measured SIV RNA in the plasma of 16 adult rhesus macaques immunized
with a live, attenuated strain of SIV (SIVmac239
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Temporal Analyses of Virus Replication, Immune Responses, and
Efficacy in Rhesus Macaques Immunized with a Live, Attenuated
Simian Immunodeficiency Virus Vaccine
nef). To evaluate the relationship between replication of the vaccine virus and the onset of protection, four animals per group were challenged with
pathogenic SIVmac251 at either 5, 10, 15, or 25 weeks after immunization. SIVmac239
nef replicated efficiently in the
immunized macaques in the first few weeks after inoculation. SIV
RNA was detected in the plasma of all animals by day 7 after
inoculation, and peak levels of viremia (105 to
107 RNA copies/ml) occurred by 7 to 12 days. Following
challenge, SIVmac251 was detected in all of the four animals challenged
at 5 weeks, in two of four challenged at 10 weeks, in none of four challenged at 15 weeks, and one of four challenged at 25 weeks. One
animal immunized with SIVmac239
nef and challenged at 10 weeks had evidence of disease progression in the absence of detectable SIVmac251. Although complete protection was not achieved at 5 weeks, a
transient reduction in viremia (approximately 100-fold) occurred in the
immunized macaques early after challenge compared to the nonimmunized
controls. Two weeks after challenge, SIV RNA was also reduced in the
lymph nodes of all immunized macaques compared with
control animals. Taken together, these results indicate that host
responses capable of reducing the viral load in plasma and lymph nodes
were induced as early as 5 weeks after immunization with
SIVmac239
nef, while more potent protection developed between 10 and
15 weeks. In further experiments, we found that resistance to SIVmac251
infection did not correlate with the presence of antibodies to SIV
gp130 and p27 antigens and was achieved in the absence of significant
neutralizing activity against the primary SIVmac251 challenge stock.
*
Corresponding author. Mailing address: Aaron Diamond
AIDS Research Center, 455 First Ave., 7th Floor, New York, NY 10016. Phone: (212) 448-5040. Fax: (212) 725-1126. E-mail:
rconnor{at}adarc.org.
Journal of Virology, September 1998, p. 7501-7509, Vol. 72, No. 9
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|